Out-patient management of chronic heart failure

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 11, 2005, Pages 1857-1881

  Terrovitis, John V ^a   Anastasiou Nana, Maria I ^b   Nanas, John N ^b  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

adrenergic blockade; Aldosterone antagonism; Ambulatory medicine; Angiotensin converting enzyme inhibition; Drug therapy; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; METFORMIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PLACEBO; PRAZOSIN; QUINAPRIL; RAMIPRIL; RENIN; ROSIGLITAZONE; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; BEHAVIOR MODIFICATION; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG RELEASE; DRUG UTILIZATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; EXERCISE; FATIGUE; FLUID RETENTION; HEADACHE; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMOFILTRATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; LACTIC ACIDOSIS; LIFESTYLE; MEDICAL SOCIETY; OUTPATIENT CARE; PERFUSION; PRACTICE GUIDELINE; PRESCRIPTION; PROGNOSIS; REVIEW; SEX DIFFERENCE; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; AMBULATORY CARE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DOBUTAMINE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HUMANS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; RANDOMIZED CONTROLLED TRIALS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 25444489028     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.11.1857     Document Type: Review

References (125)

1. HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. (2001) 38:2101-2113.
2. REMME WJ, SWEDBERG K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (2001) 22:1527-1560.
3. KANNEL WB: Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur. Heart J. (1987) 8(Suppl. F):23-26.
4. O'CONNELL JB, BRISTOW MR: Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant. (1994) 13:S107-S112.
5. STAFFORD RS, RADLEY DC: The underutilization of cardiac medications of proven benefit, 1990 to 2002. J. Am. Coll. Cardiol. (2003) 41:56-61.
6. FRANCIS GS, TANG WH: Pathophysiology of congestive heart failure. Rev. Cardiovasc. Med. (2003) 4(Suppl. 2):S14-S20.
7. GHEORGHIADE M, BONOW RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation (1998) 97:282-289.
8. JESSUP M, BROZENA S: Heart failure. N. Engl. J. Med. (2003) 348:2007-2018.
9. KJEKSHUS J, PEDERSEN TR, OLSSON AG, FAERGEMAN O, PYORALA K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. (1997) 3:249-254.
10. KOSTIS JB, DAVIS BR, CUTLER J et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA (1997) 278:212-216.
11. HE J, OGDEN LG, BAZZANO LA et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch. Intern. Med. (2001) 161:996-1002.
12. SHINDLER DM, KOSTIS JB, YUSUF S et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am. J. Cardiol. (1996) 77:1017-1020.
13. ARNOLD JM, YUSUF S, YOUNG J et al.: Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation (2003) 107:1284-1290.
14. GUERCI AD, GERSTENBLITH G, BRINKER JA et al.: A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med. (1987) 317:1613-1618.
15. HERLITZ J, WAAGSTEIN F, LINDQVIST J, SWEDBERG K, HJALMARSON A: Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am. J. Cardiol. (1997) 80:40J-44J.
16. [NO AUTHORS LISTED]: Angiotensin converting enzyme inhibition in stable coronary artery disease. The PEACE trial investigators. N. Engl. J. Med. (2004) 351:2058-2068.
17. COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1986) 314:1547-1552.
18. TAYLOR AL, ZIESCHE S, YANCY C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. (2004) 351:2049-2057.
19. IGNARRO LJ, NAPOLI C, LOSCALZO J: Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. (2002) 90:21-28.
20. [NO AUTHORS LISTED]: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. (1987) 316:1429-1435.
21. [NO AUTHORS LISTED]: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. (1991) 325:293-302.
22. COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. (1991) 325:303-310.
23. [NO AUTHORS LISTED]: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. (1992) 327:685-691.
24. PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. (1992) 327:669-677.
25. KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. (1995) 333:1670-1676.
26. [NO AUTHORS LISTED]: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet (1993) 342:821-828.
27. FLATHER MD, YUSUF S, KOBER L et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355:1575-1581.
28. YUSUF S, SLEIGHT P, POGUE J et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
29. HAVRANEK EP, ABRAMS F, STEVENS E, PARKER K: Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch. Intern. Med. (1998) 158:2024-2028.
30. SHEKELLE PG, RICH MW, MORTON SC et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J. Am. Coll. Cardiol. (2003) 41:1529-1538.
31. EXNER DV, DRIES DL, DOMANSKI MJ, COHN JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. (2001) 344:1351-1357.
32. AL-KHADRA AS, SALEM DN, RAND WM et al.: Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol. (1998) 31:419-425.
33. CICOIRA M, ZANOLLA L, FRANCESCHINI L et al.: Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (2002) 89:403-407.
34. [NO AUTHORS LISTED]: Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur. Heart J. (1998) 19:481-489.
35. NANAS JN, ALEXOPOULOS GP, ANASTASIOU-NANA MI et al.: Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J. Am. Coll. Cardiol. (2000) 36:2090-2095.
36. PACKER M, POOLE-WILSON PA, ARMSTRONG PW et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 100:2312-2318.
37. SCHOOLWERTH AC, SICA DA, BALLERMANN BJ, WILCOX CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation (2001) 104:1985-1991.
38. SHLIPAK MG: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. (2003) 138:917-924.
39. CICARDI M, ZINGALE L, BERGAMASCHINI L, AGOSTONI A: Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch. Intern. Med. (2004) 164:910-913.
40. BRISTOW MR, GINSBURG R, MINOBE W et al.: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. (1982) 307:205-211.
41. DOUGHTY RN, RODGERS A, SHARPE N, MACMAHON S: Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur. Heart J. (1997) 18:560-565.
42. HEIDENREICH PA, LEE TT, MASSIE BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1997) 30:27-34.
43. LECHAT P, PACKER M, CHALON S et al.: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98:1184-1191.
44. WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 342:1441-1446.
45. [NO AUTHORS LISTED]: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001-2007.
46. PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. (1996) 334:1349-1355.
47. [NO AUTHORS LISTED]: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 90:1765-1773.
48. [NO AUTHORS LISTED]: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9-13.
49. BROPHY JM, JOSEPH L, ROULEAU JL: Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann. Intern. Med. (2001) 134:550-560.
50. [NO AUTHORS LISTED]: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. (2001) 344:1659-1667.
51. GOLDSTEIN S, FAGERBERG B, HJALMARSON A et al.: Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J. Am. Coll. Cardiol. (2001) 38:932-938.
52. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
53. DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357:1385-1390.
54. METRA M, GIUBBINI R, NODARI S et al.: Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (2000) 102:546-551.
55. POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362:7-13.
56. ROULEAU JL, ROECKER EB, TENDERA M et al.: Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J. Am. Coll. Cardiol. (2004) 43:1423-1429.
57. YANCY CW, FOWLER MB, COLUCCI WS et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. (2001) 344:1358-1365.
58. REMME WJ, RIEGGER G, HILDEBRANDT P et al.: The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc. Drugs Ther. (2004) 18:57-66.
59. SLIWA K, NORTON GR, KONE N et al.: Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J. Am. Coll. Cardiol. (2004) 44:1825-1830.
60. WIKSTRAND J, HJALMARSON A, WAAGSTEIN F et al.: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J. Am. Coll. Cardiol. (2002) 40:491-498.
61. GATTIS WA, O'CONNOR CM, GALLUP DS, HASSELBLAD V, GHEORGHIADE M: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J. Am. Coll. Cardiol. (2004) 43:1534-1541.
62. WILKOFF BL, COOK JR, EPSTEIN AE et al.: Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA (2002) 288:3115-3123.
63. MACDONALD PS, KEOGH AM, ABOYOUN CL et al.: Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J. Am. Coll. Cardiol. (1999) 33:924-931.
64. METRA M, NODARI S, D'ALOIA A et al.: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. (2002) 40:1248-1258.
65. JONG P, DEMERS C, MCKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2002) 39:463-470.
66. MAGGIONI AP, ANAND I, GOTTLIEB S et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. (2002) 40:1414-1421.
67. GRANGER CB, MCMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772-776.
68. PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747-752.
69. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582-1587.
70. DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360:752-760.
71. COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345:1667-1675.
72. MCMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-771.
73. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
74. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
75. PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
76. JUURLINK DN, MAMDANI MM, LEE DS et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. (2004) 351:543-551.
77. PALMER BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N. Engl. J. Med. (2004) 351:585-592.
78. URETSKY BF, YOUNG JB, SHAHIDI FE et al.: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J. Am. Coll. Cardiol. (1993) 22:955-962.
79. PACKER M, GHEORGHIADE M, YOUNG JB et al.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N. Engl. J. Med. (1993) 329:1-7.
80. [NO AUTHORS LISTED]: The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. (1997) 336:525-533.
81. RATHORE SS, WANG Y, KRUMHOLZ HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med. (2002) 347:1403-1411.
82. RATHORE SS, CURTIS JP, WANG Y, BRISTOW MR, KRUMHOLZ HM: Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 289:871-878.
83. GUPTA S, NEYSES L: Diuretic usage in heart failure: a continuing conundrum in 2005. Eur. Heart J. (2005) 26(7):644-649.
84. KRAMER BK, SCHWEDA F, RIEGGER GA: Diuretic treatment and diuretic resistance in heart failure. Am. J. Med. (1999) 106:90-96.
85. GRINSTEAD WC, FRANCIS MJ, MARKS GF et al.: Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1994) 73:881-886.
86. COOPER HA, DRIES DL, DAVIS CE, SHEN YL, DOMANSKI MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100:1311-1315.
87. FARIS R, FLATHER M, PURCELL H et al.: Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int. J. Cardiol. (2002) 82:149-158.
88. DRIES DL, ROSENBERG YD, WACLAWIW MA, DOMANSKI MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J. Am. Coll. Cardiol. (1997) 29:1074-1080.
89. DUNKMAN WB, JOHNSON GR, CARSON PE et al.: Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 87(6 Suppl):VI94-VI101.
90. CLELAND JG, FINDLAY I, JAFRI S et al.: The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am. Heart J. (2004) 148:157-164.
91. CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) 6:501-508.
92. NARANG R, CLELAND JG, ERHARDT L et al.: Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur. Heart J. (1996) 17:1390-1403.
93. HALLSTROM A, PRATT CM, GREENE HL et al.: Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J. Am. Coll. Cardiol. (1995) 25:1250-1257.
94. WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral D-Sotalol. Lancet (1996) 348:7-12.
95. [NO AUTHORS LISTED]: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet (1997) 350:1417-1424.
96. SIM I, MCDONALD KM, LAVORI PW, NORBUTAS CM, HLATKY MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation (1997) 96:2823-2829.
97. DOVAL HC, NUL DR, GRANCELLI HO et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344:493-498.
98. SINGH SN, FLETCHER RD, FISHER SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med. (1995) 333:77-82.
99. JULIAN DG, CAMM AJ, FRANGIN G: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet (1997) 349:667-674.
100. BARDY GH, LEE KL, MARK DB et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. (2005) 352:225-237.
101. ELKAYAM U, AMIN J, MEHRA A et al.: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation (1990) 82:1954-1961.
102. GOLDSTEIN RE, BOCCUZZI SJ, CRUESS D, NATTEL S: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation (1991) 83:52-60.
103. [NO AUTHORS LISTED]: Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am. J. Cardiol. (1990) 66:779-785.
104. PACKER M, O'CONNOR CM, GHALI JK et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. (1996) 335:1107-1114.
105. THACKRAY S, WITTE K, CLARK AL, CLELAND JG: Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur. J. Heart Fail. (2000) 2:209-212.
106. COHN JN, ZIESCHE S, SMITH R et al.: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation (1997) 96:856-863.
107. ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356:615-620.
108. PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106:920-926.
109. TEERLINK JR: Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J. Card. Fail. (2002) 8:124-127.
110. ANAND I, MCMURRAY J, COHN JN et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 364:347-354.
111. MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-1602.
112. CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133-3140.
113. YANCY CW, SALTZBERG MT, BERKOWITZ RL et al.: Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am. J. Cardiol. (2004) 94:595-601.
114. NOHRIA A, LEWIS E, STEVENSON LW: Medical management of advanced heart failure. JAMA (2002) 287:628-640.
115. PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. (1991) 325:1468-1475.
116. HAMPTON JR, VAN VELDHUISEN DJ, KLEBER FX et al.: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet (1997) 349:971-977.
117. COHN JN, GOLDSTEIN SO, GREENBERG BH et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. (1998) 339:1810-1816.
118. SHAKAR SF, ABRAHAM WT, GILBERT E et al.: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J. Am. Coll. Cardiol. (1998) 31:1336-1340.
119. NANAS JN, TSAGALOU EP, KANAKAKIS J et al.: Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest (2004) 125:1198-1204.
120. FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360:196-202.
121. NANAS JN, PAPAZOGLOU P, TSAGALOU EP et al.: Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am. J. Cardiol. (2005) 95:768-771.
122. SILVER MA, MAISEL A, YANCY CW et al.: BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest. Heart Fail. (2004) 10:1-30.
123. TROUGHTON RW, FRAMPTON CM, YANDLE TG et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 355:1126-1130.
124. YOSHIZAWA A, YOSHIKAWA T, NAKAMURA I et al.: Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J. Card. Fail. (2004) 10:310-315.
125. PACKER M: Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation (2003) 108:2950-2953.